Boehringer Ingelheim
Boehringer Ingelheim Expands Oncology Pipeline via Strategic Collaboration with Tempus AI
Boehringer Ingelheim; Tempus AI; oncology; cancer research; real-world data; AI; biomarker discovery; drug development; strategic collaboration
Boehringer Ingelheim’s Iclepertin Fails to Meet Primary and Secondary Endpoints in Phase III Schizophrenia Trials
Boehringer Ingelheim, iclepertin, schizophrenia, Phase III trials, cognitive impairment, CONNEX program
Boehringer Ingelheim Discontinues NPY2 Obesity Drug Development with Gubra, Focuses on Triple-Agonist Candidate
Boehringer Ingelheim, Gubra, obesity drug, NPY2, triple-agonist, BI 3034701, clinical trials